



Express Mail Mailing Label No. EV926971838US

PATENT  
Attorney Docket No. BCF-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gaudreau CONFIRMATION NO.: 7604  
APPLICATION NO.: 10/527,598 GROUP NO.: 1654  
FILING DATE: November 3, 2005 EXAMINER: Bradley, Christina  
TITLE: GHRH Analogues

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

**REMARKS**


In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) above but before the mailing date of any of a **final action** under 37 C.F.R. 1.113, a **notice of allowance** under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein; or

- ☐ (3) after the period defined in (2) above but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Fangli Chen, Ph.D.  
Attorney for Applicant(s)  
Kirkpatrick & Lockhart Preston  
Gates Ellis LLP  
State Street Financial Center  
One Lincoln Street  
Boston, Massachusetts 02111-2950

Date: May 25, 2007  
Reg. No. 51,551

Tel. No.: (617) 261-3198  
Fax No.: (617) 261-3175



FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: BCF-001 APPLICANT(S): Gaudreau APPLICATION NO.: 10/527,598 FILING DATE: November 3, 2005 GROUP NO.: 1654
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C1	Boulanger et al., "Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver," <u>Peptides</u> , 13:681-689 (1992).
	C2	Boulanger et al., "Proteolytic degradation of rat growth hormone-releasing factor(1-29) amide in rat pituitary and hypothalamus," <u>Brain Res.</u> , 616:39-47 (1993).
	C3	Boulanger et al., "Development of a site-directed polyclonal antibody against the pituitary growth hormone-releasing hormone receptor and its use to estimate GHRH receptor concentration in normal and hypothyroid rats," <u>Neuroendocrinology</u> , 70:117-127 (1999).
	C4	Cuttler et al., "Short stature and growth hormone therapy: A national study of physician recommended patterns," <u>JAMA</u> , 276(7):531-537 (1996).
	C5	Dubreuil et al., "Long-term growth hormone-releasing factor administration on growth hormone, insulin-like growth factor-I concentrations, and bone healing in the beagle," <u>Can. J. Vet. Res.</u> , 60:7-13 (1996).
	C6	Farmer et al., "Carcass composition and resistance to fasting in neonatal piglets born of sow immunized against somatostatin and/or receiving growth hormone-releasing factor injections during gestation," <u>Biol. Neonate</u> , 61:110-117 (1992).
	C7	Finklestein et al., "Insurance coverage, physician recommendations, and access to emerging treatments," <u>JAMA</u> , 279(9):663-668 (1998).
	C8	Gaudreau et al., "Structure-function studies of peptides inhibiting the ribonucleotide reductase activity of herpes simplex virus type I," <u>J. Med. Chem.</u> , 35:346-350 (1992).
	C9	Girard et al., "Pharmokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses," <u>Eur. J. Clin. Pharmacol.</u> , 32:507-513 (1987).
	C10	Kimura et al., "Ultradian rhythm of growth hormone secretion and sleep in the adult male rat," <u>J. Physiol.</u> , 353:305-315 (1984).
	C11	Lapierre et al., "Effects of growth hormone-releasing factor and feed intake on energy metabolism in growing beef steers: Whole body energy and nitrogen metabolism," <u>J. Anim. Sci.</u> , 70:764-772 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------



FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: BCF-001 APPLICANT(S): Gaudreau APPLICATION NO.: 10/527,598 FILING DATE: November 3, 2005 GROUP NO.: 1654
	C12	Lappier et al., "The effect of feed intake and growth hormone-release factor on lactating dairy cows," <u>J. Dairy Sci.</u> , 78:804-815 (1995).
	C13	Mitsugi et al., "Simultaneous determination of blood levels of corticosterone and growth hormone in the male rat: Relation to sleep-wakefulness cycle," <u>Neuroendocrinology</u> , 41:125-130 (1985).
	C14	Van Cauter et al., "Interrelations between sleep and the somatotrophic axis," <u>Sleep</u> , 21(6):553-566 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------